Neoadjuvant personalized cancer vaccines: the final frontier?
ABSTRACTIntroduction Clinical trials of personalized cancer vaccines have shown that on-demand therapies that are manufactured for each patient, result in activated T cell responses against individual tumor neoantigens. However, their use has been traditionally restricted to adjuvant settings and la...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | Expert Review of Vaccines |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2303015 |